Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences
Alkermes plc - Ordinary Shares (ALKS)
Last alkermes plc - ordinary shares earnings: 4/29 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
phx.corporate-ir.net/phoenix.zhtml?c=92211&p=irol-irhome
Company Research
Source: PR Newswire
– 12 Poster Presentations Showcase Research in Schizophrenia, Bipolar I Disorder and Narcolepsy –– Results Presented From Real-World Retrospective Study of Healthcare Resource Utilization and Treatment Patterns in Patients With Schizophrenia or Bipolar I Disorder Following Initiation of LYBALVI®(olanzapine and samidorphan) –DUBLIN, Nov. 7, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of research related to LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil), the company's commercial products in psychiatry, and ALKS 2680, an investigational medicine in development as a once-daily treatment for narcolepsy and idiopathic hypersomnia, at two scientific conferences this fall. The two meetings—the 37th Annual Psych Congress (Psych Congress), which took place Oct. 29-Nov. 2, 2024 in Boston, and the 2024 Neuroscience Education Institute (NEI) Congress, taking place Nov. 7-10, 2024 in Colorado Springs, Colorado—represent important op
Show less
Read more
Impact Snapshot
Event Time:
ALKS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALKS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALKS alerts
High impacting Alkermes plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
ALKS
News
- Alkermes plc (NASDAQ: ALKS) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $30.00 to $32.00. They now have a "buy" rating on the stock.MarketBeat
- Alkermes plc (NASDAQ: ALKS) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.MarketBeat
- Alkermes plc (NASDAQ: ALKS) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $46.00 price target on the stock.MarketBeat
- Alkermes plc 2024 Q4 - Results - Earnings Call Presentation [Seeking Alpha]Seeking Alpha
- Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025 [Yahoo! Finance]Yahoo! Finance
ALKS
Earnings
- 2/12/25 - Beat
ALKS
Sec Filings
- 2/14/25 - Form 4
- 2/13/25 - Form 144
- 2/12/25 - Form 10-K
- ALKS's page on the SEC website